CTLA4 and rheumatoid arthritis: Clinical signal backs the axis: CD40L antagonism with dazodalibep improved systemic activity and symptoms in a phase-2 Sjögren’s trial, while broad co-stimulation dampening (CTLA-4-Ig) remains a benchmark in RA.